NASDAQ$LGND
Ligand Pharmaceuticals Incorporated · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported strong first quarter financial results driven by Captisol sales and raised 2020 financial guidance.
Ligand Pharmaceuticals reported first quarter financial results with total revenues of $33.2 million, driven by strong Captisol sales, and raised its 2020 financial guidance to approximately $140 million in total revenues and $3.65 diluted EPS.
- First quarter revenues were $33.2 million, compared to $43.5 million for the same period in 2019.
- Captisol sales were $21.1 million, up from $9.0 million in the prior year, driven by sales for remdesivir.
- Net loss was $(24.1) million, or $(1.46) per diluted share, compared to net income of $666.3 million, or $31.32 per diluted share, for the same period in 2019.
- Ligand is raising its 2020 financial guidance to approximately $140 million in total revenues and diluted EPS to be $3.65.
Headline financials
Revenue & EPS history
Ligand · Revenue · Quarterly
$33.2M
Revenue by segment
Ligand · $27.7M total across 2 segments · Q1 2020
- Captisol Sales$21.1M+135.6%76.3%
- Royalties$6.57M-66.4%23.7%
Forward guidance
Ligand is raising its 2020 financial guidance. Ligand now expects 2020 total revenues to be approximately $140 million and diluted EPS to be $3.65.
Tailwinds
- Higher sales of Captisol
Headwinds
- Reductions in royalties
- Reductions in contract revenue
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+0.1%
Avg return
Earnings day
+2.0%
Avg return
5 days after
-0.5%
Avg return
30 days after
52%
33 / 64 earnings
Positive
+18.7%
Q4 2013
Best reaction
-21.6%
Q3 2011
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.5% | +5.2% | +12.9% | |
| Q4 2025 | +2.6% | +6.7% | +2.1% | |
| Q3 2025 | +9.3% | +9.6% | -2.9% | |
| Q1 2025 | -3.2% | +0.0% | +0.4% | |
| Q4 2024 | +0.6% | +0.2% | -6.4% | |
| Q3 2024 | +3.7% | +3.3% | +6.8% | |
| Q2 2024 | -4.9% | +2.1% | +5.1% | |
| Q1 2024 | +10.3% | +19.8% | +13.1% | |
| Q4 2023 | +13.3% | +5.8% | -1.8% | |
| Q3 2023 | +2.8% | +3.8% | +16.3% | |
| Q2 2023 | +6.7% | +1.4% | -4.2% | |
| Q1 2023 | +5.2% | +3.2% | -0.2% | |
| Q4 2022 | +5.9% | +3.0% | -2.1% | |
| Q3 2022 | +12.8% | +31.3% | +6.0% | |
| Q2 2022 | +5.7% | +9.5% | -3.5% | |
| Q1 2022 | -2.9% | -13.0% | -9.1% | |
| Q4 2021 | -16.3% | -19.7% | -8.7% | |
| Q3 2021 | +7.8% | +4.9% | -6.9% | |
| Q2 2021 | -8.1% | -10.0% | -7.4% | |
| Q1 2021 | -9.5% | -10.5% | -22.3% | |
| Q4 2020 | +1.7% | +17.6% | -18.5% | |
| Q3 2020 | -0.2% | +5.4% | +3.4% | |
| Q2 2020 | +0.6% | +0.4% | -11.9% | |
| Q1 2020 | +3.2% | +6.8% | +22.1% | |
| Q4 2019 | +3.3% | +2.8% | +16.7% | |
| Q3 2019 | -7.4% | -1.4% | -4.9% | |
| Q2 2019 | -14.8% | -11.5% | -14.7% | |
| Q1 2019 | -3.3% | -4.1% | -14.6% | |
| Q4 2018 | -2.7% | +1.8% | -10.0% | |
| Q3 2018 | -2.7% | -8.9% | -10.7% | |
| Q2 2018 | +9.8% | +7.7% | +13.0% | |
| Q1 2018 | +7.3% | +13.2% | +26.4% | |
| Q4 2017 | +0.0% | -1.9% | +3.7% | |
| Q3 2017 | -4.9% | -1.3% | -8.4% | |
| Q2 2017 | +5.7% | +2.5% | +9.4% | |
| Q1 2017 | -2.9% | +0.2% | +1.2% | |
| Q4 2016 | -2.8% | +1.3% | +1.5% | |
| Q3 2016 | -2.7% | +3.1% | +10.8% | |
| Q2 2016 | -7.4% | -13.2% | -20.2% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -4.2% | — | — | |
| Q3 2015 | +5.1% | — | — | |
| Q2 2015 | +2.3% | — | — | |
| Q1 2015 | +4.5% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -3.9% | — | — | |
| Q2 2014 | +7.7% | — | — | |
| Q1 2014 | -2.9% | — | — | |
| Q4 2013 | +18.7% | — | — | |
| Q3 2013 | -10.7% | — | — | |
| Q2 2013 | -1.7% | — | — | |
| Q1 2013 | +1.7% | — | — | |
| Q4 2012 | +7.4% | — | — | |
| Q3 2012 | +10.8% | — | — | |
| Q2 2012 | -8.8% | — | — | |
| Q4 2011 | -8.8% | — | — | |
| Q1 2012 | +1.3% | — | — | |
| Q3 2011 | -21.6% | — | — | |
| Q2 2011 | -6.5% | — | — | |
| Q1 2011 | +0.9% | — | — | |
| Q4 2010 | -0.3% | — | — | |
| Q3 2010 | -2.4% | — | — | |
| Q2 2010 | -3.6% | — | — | |
| Q1 2010 | -9.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro